| pubmed-article:11074153 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11074153 | lifeskim:mentions | umls-concept:C0038585 | lld:lifeskim |
| pubmed-article:11074153 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:11074153 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:11074153 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:11074153 | lifeskim:mentions | umls-concept:C0449774 | lld:lifeskim |
| pubmed-article:11074153 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:11074153 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:11074153 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11074153 | pubmed:dateCreated | 2001-1-4 | lld:pubmed |
| pubmed-article:11074153 | pubmed:abstractText | Substance P, which modulates synaptic excitability, can be induced by a variety of stimuli. We studied the expression of hippocampal substance P in rats in using lithium-pilocarpine model of status epilepticus during development. Status epilepticus resulted in an age-specific manner of substance P expression that was anatomically distinctive in hippocampal subfields. Maximal induction of substance P immunoreactivity was seen in the CA1 region of the two-week-old rats, and progressively decreased in the three-, four-week-old rats and adults. Meanwhile, the number of substance P-immunoreactive neurons in the CA3 region and dentate granule cell layer was minimal in the two-week-old animals, but approximated the adult level in the three- and four-week-old rats. No substance P-immunoreactive axon terminals were seen in the strata pyramidale and lucidum in the CA3 region of the two-week-old rats, but they were found to progressively increase in the three-, four-week-old rats and adults. To confirm substance P expression after status epilepticus, we studied the expression of preprotachykinin-A mRNA in the hippocampus of the three-week-old rats by in situ hybridization. Two hours following injection of lithium-pilocarpine, preprotachykinin-A mRNA dramatically increased in the granule cells, as well as in the CA3 and CA1 pyramidal cell layers of the hippocampus. To evaluate the relationship between behavioral seizures and substance P induction, we used the NMDA receptor antagonist MK-801. Injection of MK-801 completely blocked lithium-pilocarpine-induced behavioral seizures and SP induction in the two-week-old rats. These results indicate that seizure activity selectively evokes age-dependent and region-selective expression of substance P. | lld:pubmed |
| pubmed-article:11074153 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11074153 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11074153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11074153 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11074153 | pubmed:issn | 0306-4522 | lld:pubmed |
| pubmed-article:11074153 | pubmed:author | pubmed-author:ShinD HDH | lld:pubmed |
| pubmed-article:11074153 | pubmed:author | pubmed-author:LiuHH | lld:pubmed |
| pubmed-article:11074153 | pubmed:author | pubmed-author:WasterlainC... | lld:pubmed |
| pubmed-article:11074153 | pubmed:author | pubmed-author:MazaratiA MAM | lld:pubmed |
| pubmed-article:11074153 | pubmed:author | pubmed-author:SankarRR | lld:pubmed |
| pubmed-article:11074153 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11074153 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:11074153 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11074153 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11074153 | pubmed:pagination | 297-304 | lld:pubmed |
| pubmed-article:11074153 | pubmed:dateRevised | 2009-11-3 | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:meshHeading | pubmed-meshheading:11074153... | lld:pubmed |
| pubmed-article:11074153 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11074153 | pubmed:articleTitle | Patterns of status epilepticus-induced substance P expression during development. | lld:pubmed |
| pubmed-article:11074153 | pubmed:affiliation | Epilepsy Research Laboratory, Veteran Administration Medical Center, Sepulveda, CA 91343, USA. htliu@ucla.edu | lld:pubmed |
| pubmed-article:11074153 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11074153 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11074153 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11074153 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11074153 | lld:pubmed |
